Do analysts prefer PDSB or BKHA?

PDS Biotechnology presently has a consensus target price of $9.00, suggesting a potential upside of 4,117.43%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, equities analysts clearly believe PDS Biotechnology is more favorable than Black Hawk Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, PDSB or BKHA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PDS Biotechnology N/A N/A -$34.50M -$0.64 N/A Black Hawk Acquisition N/A N/A N/A N/A N/A

Is PDSB or BKHA more profitable?

Black Hawk Acquisition's return on equity of 0.00% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets PDS Biotechnology N/A -708.18% -136.50% Black Hawk Acquisition N/A N/A N/A

Does the media prefer PDSB or BKHA?

In the previous week, PDS Biotechnology had 7 more articles in the media than Black Hawk Acquisition. MarketBeat recorded 9 mentions for PDS Biotechnology and 2 mentions for Black Hawk Acquisition. Black Hawk Acquisition's average media sentiment score of 0.85 beat PDS Biotechnology's score of 0.77 indicating that Black Hawk Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Hawk Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MGX or PDSB?

In the previous week, PDS Biotechnology had 6 more articles in the media than Metagenomi. MarketBeat recorded 9 mentions for PDS Biotechnology and 3 mentions for Metagenomi. PDS Biotechnology's average media sentiment score of 0.77 beat Metagenomi's score of 0.62 indicating that PDS Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALGS or PDSB?

In the previous week, PDS Biotechnology had 7 more articles in the media than Aligos Therapeutics. MarketBeat recorded 9 mentions for PDS Biotechnology and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.93 beat PDS Biotechnology's score of 0.77 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MREO or PDSB more profitable?

Mereo BioPharma Group's return on equity of -74.82% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group N/A -74.82% -64.28% PDS Biotechnology N/A -708.18% -136.50%

Does the media prefer PDSB or GOSS?

In the previous week, Gossamer Bio had 4 more articles in the media than PDS Biotechnology. MarketBeat recorded 13 mentions for Gossamer Bio and 9 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 0.77 beat Gossamer Bio's score of 0.29 indicating that PDS Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

PDS Biotechnology (PDSB) Competitors

$0.21 +0.00 (+1.19%)

As of 01:39 PM Eastern

Compare

PDSB vs. BKHA, MGX, ALGS, MREO, and GOSS

Should you buy PDS Biotechnology stock or one of its competitors? PDS Biotechnology's main competitors and comparable companies include Black Hawk Acquisition (BKHA), Metagenomi (MGX), Aligos Therapeutics (ALGS), Mereo BioPharma Group (MREO), and Gossamer Bio (GOSS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PDS Biotechnology compare to Black Hawk Acquisition?

PDS Biotechnology (NASDAQ:PDSB) and Black Hawk Acquisition (NASDAQ:BKHA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A

PDS Biotechnology has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Comparatively, Black Hawk Acquisition has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

26.8% of PDS Biotechnology shares are held by institutional investors. 8.4% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, PDS Biotechnology had 7 more articles in the media than Black Hawk Acquisition. MarketBeat recorded 9 mentions for PDS Biotechnology and 2 mentions for Black Hawk Acquisition. Black Hawk Acquisition's average media sentiment score of 0.85 beat PDS Biotechnology's score of 0.77 indicating that Black Hawk Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PDS Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Black Hawk Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

PDS Biotechnology presently has a consensus target price of $9.00, suggesting a potential upside of 4,117.43%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, equities analysts clearly believe PDS Biotechnology is more favorable than Black Hawk Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Black Hawk Acquisition's return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-708.18%	-136.50%
Black Hawk Acquisition	N/A	N/A	N/A

Summary

PDS Biotechnology beats Black Hawk Acquisition on 7 of the 10 factors compared between the two stocks.

How does PDS Biotechnology compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

26.8% of PDS Biotechnology shares are held by institutional investors. 12.5% of Metagenomi shares are held by company insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Metagenomi currently has a consensus price target of $6.00, indicating a potential upside of 408.47%. PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 4,117.43%. Given PDS Biotechnology's higher possible upside, analysts clearly believe PDS Biotechnology is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

PDS Biotechnology has lower revenue, but higher earnings than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.77	-$87.87M	-$2.49	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A

In the previous week, PDS Biotechnology had 6 more articles in the media than Metagenomi. MarketBeat recorded 9 mentions for PDS Biotechnology and 3 mentions for Metagenomi. PDS Biotechnology's average media sentiment score of 0.77 beat Metagenomi's score of 0.62 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PDS Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PDS Biotechnology has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-63.65%	-44.52%
PDS Biotechnology	N/A	-708.18%	-136.50%

Metagenomi has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

Summary

PDS Biotechnology beats Metagenomi on 9 of the 15 factors compared between the two stocks.

How does PDS Biotechnology compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Aligos Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 540.60%. PDS Biotechnology has a consensus target price of $9.00, indicating a potential upside of 4,117.43%. Given PDS Biotechnology's higher possible upside, analysts plainly believe PDS Biotechnology is more favorable than Aligos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

PDS Biotechnology has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Aligos Therapeutics' return on equity of -160.72% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
PDS Biotechnology	N/A	-708.18%	-136.50%

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Aligos Therapeutics has higher revenue and earnings than PDS Biotechnology. Aligos Therapeutics is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	17.12	-$24.19M	-$7.30	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A

In the previous week, PDS Biotechnology had 7 more articles in the media than Aligos Therapeutics. MarketBeat recorded 9 mentions for PDS Biotechnology and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.93 beat PDS Biotechnology's score of 0.77 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PDS Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aligos Therapeutics has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

Summary

Aligos Therapeutics beats PDS Biotechnology on 10 of the 16 factors compared between the two stocks.

How does PDS Biotechnology compare to Mereo BioPharma Group?

Mereo BioPharma Group (NASDAQ:MREO) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Mereo BioPharma Group currently has a consensus price target of $1.67, indicating a potential upside of 515.46%. PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 4,117.43%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than Mereo BioPharma Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

PDS Biotechnology has lower revenue, but higher earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	86.49	-$41.88M	-$0.04	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A

Mereo BioPharma Group's return on equity of -74.82% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-74.82%	-64.28%
PDS Biotechnology	N/A	-708.18%	-136.50%

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Mereo BioPharma Group has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market.

In the previous week, PDS Biotechnology had 8 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 9 mentions for PDS Biotechnology and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 1.87 beat PDS Biotechnology's score of 0.77 indicating that Mereo BioPharma Group is being referred to more favorably in the media.

Company	Overall Sentiment
Mereo BioPharma Group	Very Positive
PDS Biotechnology	Positive

Summary

Mereo BioPharma Group and PDS Biotechnology tied by winning 7 of the 14 factors compared between the two stocks.

How does PDS Biotechnology compare to Gossamer Bio?

PDS Biotechnology (NASDAQ:PDSB) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

PDS Biotechnology has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-708.18%	-136.50%
Gossamer Bio	-235.00%	N/A	-112.04%

PDS Biotechnology has higher earnings, but lower revenue than Gossamer Bio. PDS Biotechnology is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A
Gossamer Bio	$48.47M	0.85	-$170.37M	-$0.70	N/A

PDS Biotechnology currently has a consensus target price of $9.00, indicating a potential upside of 4,117.43%. Gossamer Bio has a consensus target price of $3.20, indicating a potential upside of 1,724.40%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than Gossamer Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

In the previous week, Gossamer Bio had 4 more articles in the media than PDS Biotechnology. MarketBeat recorded 13 mentions for Gossamer Bio and 9 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 0.77 beat Gossamer Bio's score of 0.29 indicating that PDS Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PDS Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

PDS Biotechnology has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market.

26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 8.4% of PDS Biotechnology shares are owned by company insiders. Comparatively, 3.7% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Gossamer Bio beats PDS Biotechnology on 8 of the 15 factors compared between the two stocks.

Get PDS Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PDSB vs. The Competition

Export

Metric	PDS Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.94M	$3.92B	$7.13B	$12.81B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-0.33	11.77	272.85	25.45
Price / Sales	N/A	1,393.83	685.78	122.48
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	1.19	16.75	11.02	6.33
Net Income	-$34.50M	-$22.71M	$3.47B	$349.46M
7 Day Performance	-1.57%	2.15%	0.94%	-0.29%
1 Month Performance	-68.90%	12.31%	7.93%	4.18%
1 Year Performance	-82.79%	53.90%	23.74%	14.53%

PDS Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PDSB PDS Biotechnology	2.8407 of 5 stars	$0.21 +1.2%	$9.00 +4,117.4%	-83.0%	$11.94M	N/A	N/A	20	Analyst Revision
BKHA Black Hawk Acquisition	N/A	$11.79 -0.8%	N/A	+7.4%	$48.93M	N/A	N/A	N/A
MGX Metagenomi	3.2118 of 5 stars	$1.24 +2.1%	$6.00 +385.8%	-31.6%	$46.66M	$25.21M	N/A	236
ALGS Aligos Therapeutics	3.6764 of 5 stars	$7.35 +6.0%	$38.50 +424.2%	-34.5%	$45.83M	$2.19M	N/A	90
MREO Mereo BioPharma Group	3.2098 of 5 stars	$0.29 -1.2%	$1.67 +482.8%	-85.2%	$45.67M	$500K	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PDSB) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PDS Biotechnology (PDSB) Competitors

PDSB vs. BKHA, MGX, ALGS, MREO, and GOSS

How does PDS Biotechnology compare to Black Hawk Acquisition?

Summary

How does PDS Biotechnology compare to Metagenomi?

Summary

How does PDS Biotechnology compare to Aligos Therapeutics?

Summary

How does PDS Biotechnology compare to Mereo BioPharma Group?

Summary

How does PDS Biotechnology compare to Gossamer Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PDS Biotechnology (PDSB) Competitors

PDSB vs. BKHA, MGX, ALGS, MREO, and GOSS

How does PDS Biotechnology compare to Black Hawk Acquisition?

Which has preferable earnings and valuation, PDSB or BKHA?

Which has more risk & volatility, PDSB or BKHA?

Do insiders & institutionals hold more shares of PDSB or BKHA?

Does the media prefer PDSB or BKHA?

Do analysts prefer PDSB or BKHA?

Is PDSB or BKHA more profitable?

Summary

How does PDS Biotechnology compare to Metagenomi?

Do insiders & institutionals have more ownership in MGX or PDSB?

Do analysts recommend MGX or PDSB?

Which has preferable valuation & earnings, MGX or PDSB?

Does the media favor MGX or PDSB?

Is MGX or PDSB more profitable?

Which has more volatility & risk, MGX or PDSB?

Summary

How does PDS Biotechnology compare to Aligos Therapeutics?

Do analysts recommend ALGS or PDSB?

Is ALGS or PDSB more profitable?

Do institutionals and insiders have more ownership in ALGS or PDSB?

Which has stronger earnings and valuation, ALGS or PDSB?

Does the media favor ALGS or PDSB?

Which has more risk and volatility, ALGS or PDSB?

Summary

How does PDS Biotechnology compare to Mereo BioPharma Group?

Do analysts prefer MREO or PDSB?

Which has better valuation and earnings, MREO or PDSB?

Is MREO or PDSB more profitable?

Do institutionals & insiders have more ownership in MREO or PDSB?

Which has more risk & volatility, MREO or PDSB?

Does the media favor MREO or PDSB?

Summary

How does PDS Biotechnology compare to Gossamer Bio?

Is PDSB or GOSS more profitable?

Which has stronger earnings & valuation, PDSB or GOSS?

Do analysts prefer PDSB or GOSS?

Does the media prefer PDSB or GOSS?

Which has more volatility & risk, PDSB or GOSS?

Do institutionals and insiders believe in PDSB or GOSS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools